CN-105 helps improve recovery after brain bleeding.
CN-105 Improves Functional Outcome After Intracranial Hemorrhage
['FUNDING_OTHER'] · AEGISCN, LLC · NIH-10935969
This study is looking at how a new treatment called CN-105 might help people who have had a serious brain bleed called intracerebral hemorrhage by reducing inflammation and protecting brain cells, with the hope of improving their recovery and everyday functioning.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | AEGISCN, LLC (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10935969 on ClinicalTrials.gov |
What this research studies
This research investigates the effects of CN-105, a specially designed peptide, on patients who have suffered from intracerebral hemorrhage (ICH), a serious type of brain bleeding. The study aims to determine if CN-105 can enhance recovery by reducing inflammation and protecting brain cells. Patients will be monitored for improvements in cognitive and physical functions following treatment. The research builds on promising preclinical results and aims to transition into clinical trials to evaluate safety and efficacy in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently experienced an intracerebral hemorrhage.
Not a fit: Patients who have not suffered from an intracerebral hemorrhage or those with contraindications to the treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly improves recovery outcomes for patients after brain hemorrhages.
How similar studies have performed: Previous research has shown promising results with similar anti-inflammatory approaches in neurological recovery, suggesting potential for success in this novel application.
Where this research is happening
DURHAM, UNITED STATES
- AEGISCN, LLC — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BENNETT, ELLEN — AEGISCN, LLC
- Study coordinator: BENNETT, ELLEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.